Khloris Biosciences is at the forefront of innovative medical treatments, focusing on the development of cancer vaccines and therapies utilizing induced pluripotent stem cells (iPSCs). This technology allows the company to harness the unique immunotherapeutic potential of iPSCs for drug discovery, vaccine development, and cell therapies. By leveraging patient-derived iPSCs, Khloris aims to create personalized cancer vaccines, which represent a significant advancement in the fight against cancer. Additionally, the company is pioneering the use of iPSC-derived cardiomyocytes, which are specialized heart cells, to address cardiovascular diseases, showcasing their commitment to improving health outcomes across multiple medical fields.

The company's approach not only emphasizes the revolutionary potential of iPSCs in cancer treatment but also highlights their unique position as a leader in the application of this technology for cardiovascular medicine. Khloris Biosciences is dedicated to redefining the future of medical treatment and prevention, with a mission to create a world without cancer. Their innovative platforms and ongoing research reflect a strong commitment to advancing healthcare through cutting-edge science and technology.

United States

Khloris Biosciences is a private biotechnology company located in the San Francisco Bay Area. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies.

Khloris Biosciences

Company Details